Phase 2 N=12 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
Cutaneous Lupus · Systemic Lupus Erythematosus
Primary: Oral Clearance (CL/F) (Cohort 1 Only) — 28.4 (L/hr)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency
Short Stature
Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score
Phase 2 N=50 Exploratory Propofol Dose Finding Study In Neonates
Adverse Reaction to Drug · Neonatal Disorder
Primary: Effective Dose for 50% of Patients for Succesful Intubation and Subsequent Extubation in Case of Planned Extubation After INSURE Procedure — 0.792; 0.713; 1.350 mg/kg
Phase 3 N=121 Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
Primary Pulmonary Hypertension
Primary: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events — 121 Participants
Phase 2 N=38 Systems Biology of Zoster Vaccine
Zoster · Zoster Varicella · Shingles
Primary: Change in Innate Immune Signatures Post-vaccine Dose — 1.6801; 2.096; -0.5609; -1.1284 Normalized Enrichment Score (NES)
N/A N=29 Investigational Oocyte Cryopreservation for Medical and Non Medical Indications
Infertility, Female · Deferred Childbearing
Primary: Fertility Quality of Life Questionnaire Completed After One Year After Oocyte Cryopreservation for Non-medical Reasons — 9 Participants
Phase 2 N=257 Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
Dry Eye
Primary: Total Corneal Fluorescein Staining — 7.35; 7.25; 7.12 score on a scale
N/A N=18 The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function
Endothelial Dysfunction
Primary: Endothelial Function — 3.31; 3.53 millimeters
Phase 4 N=63 Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
Abuse Potential
Primary: Drug Liking Visual Analog Scale (VAS) — 56.4; 84.9; 59.6; 64.6 score on a scale
Phase 4 N=508 Research and Innovation to Stop E-cigarette/Vaping in Young Adults
Nicotine Dependence · E-Cig Use
Primary: 7-day Point Prevalence Vaping Abstinence — 55; 54; 61; 59 Participants — p=0.14
Phase 3 N=467 Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Time-averaged Proportional Change in NT proBNP From Baseline to Weeks 4 and 8 — 0.7200; 0.8425 Geometric Mean Ratio — p=0.0492
N/A N=22 Effect of Inulin-type Fructans on Constipated Children.
Constipation
Primary: Stool Consistency — 2.57; 1.63 units on a scale
N/A N=51 Treatment of Surgical Scars Following Breast Augmentation, Abdominoplasty or Face Lift
Surgical Scar · Breast Augmentation · Abdominoplasty
Primary: Improvement of Surgical Scars at 12 Months Compared to Baseline (Pre-treatment) as Evaluated by 3 Independent Blinded Reviewers Using the General Aesthetic Improvement…
Phase 2 N=75 Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)
Myelodysplastic Syndromes
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 75 Participants
Phase 2 N=116 Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
Anemia
Primary: Percentage of Low Transfusion Burden (LTB) Participants With Modified Erythroid Response (mHI-E) — 0; 0; 66.7; 100 Percentage of participants